Country: Malta
Language: English
Source: Medicines Authority
CISPLATIN
Mylan S.A.S. 117 Allee des Parcs, 69800 Saint Priest, France
L01XA01
CISPLATIN 1 mg/ml
CONCENTRATE FOR SOLUTION FOR INFUSION
CISPLATIN 1 mg/ml
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2013-07-08
Page 1 of 11 PACKAGE LEAFLET: INFORMATION FOR THE USER CISPLATIN MYLAN 1 MG/ML, CONCENTRATE FOR SOLUTION FOR INFUSION Cisplatin READ ALL OF THIS_ _LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - This medicine has been prescribed for you. Do not_ _pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Cisplatin Mylan is and what it is used for 2. Before you use Cisplatin Mylan 3. How you use Cisplatin Mylan 4. Possible side effects 5. How to store Cisplatin Mylan 6. Further information CISPLATIN MYLAN CONCENTRATE FOR SOLUTION FOR INFUSION IS GIVEN ONLY BY HEALTHCARE PERSONNEL,WHO CAN REPLY TO ANY QUESTIONS, WHICH YOU MAY HAVE AFTER READING THIS PACKAGE LEAFLET. 1. WHAT CISPLATIN MYLAN IS AND WHAT IT IS USED FOR Cisplatin forms part of a group of medicines called cytostatics, which are used in the treatment of cancer. Cisplatin can be used alone but more commonly Cisplatin is used in combination with other cytostatics. WHAT IS IT USED FOR? Cisplatin can destroy cells in your body that may cause certain types of cancer (tumor of testis, tumor of ovary, tumor of the bladder, head and neck epithelial tumor, lung cancer and for cervical cancer in combination with radiotherapy). Your doctor will be able to provide you with more information. _ _ 2. BEFORE YOU USE CISPLATIN MYLAN DO NOT TAKE CISPLATIN MYLAN IF: • you are allergic (hypersensitive) to cisplatin or to any of the other ingredients Read the complete document
Page 1 of 15 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cisplatin Mylan 1 mg/ml, concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 1 mg of cisplatin. One vial of 50 ml concentrate for solution for infusion contains 50 mg of cisplatin. One vial of 100 ml concentrate for solution for infusion contains 100 mg of cisplatin. Excipient : Each ml of solution contains 9 mg (< 1mmol) of sodium. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless to pale yellow solution free from visible particles The pH is between 3,5 and 6,5. The osmoloarity is between 262 and 363 mOsmol/L. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cisplatin Mylan is intended for the treatment of: advanced or metastasised testicular cancer advanced or metastasised ovarian cancer advanced or metastasised bladder carcinoma advanced or metastasised squamous cell carcinoma of the head and neck advanced or metastasised non-small cell lung carcinoma advanced or metastasised small cell lung carcinoma. Cisplatin is indicated in combination with radiotherapy in the treatment of cervical carcinoma. Cisplatin can be used as monotherapy and in combination therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Cisplatin Mylan 1 mg/ml concentrate for solution for infusion is to be diluted before administration. For instructions on dilution of the product before administration see section 6.6. The diluted solution should be administered only intravenously by infusion (see below). For administration, any device containing aluminium that may come in contact with cisplatin (sets Read the complete document